1. Pink Sheet

Achilles On Getting ‘New Wave’ Immunotherapy From Concept To Clinic In Three Years

 
• By Neena Brizmohun

Clonal neoantigen immunotherapy developer Achilles Therapeutics tells the Pink Sheet how the regulatory landscape for advanced therapies might not be as tricky as it used to be.

Lab
Achilles is set to start testing its monoclonal neoantigen-based therapy in humans • Source: Shutterstock

Achilles Therapeutics is convinced that the timing could not be better when it comes to navigating its next-generation, personalized T cell therapy for solid tumors through the historically challenging regulatory landscape for advanced therapies.

The company has managed to take its investigational clonal neoantigen-based therapy from a concept on the whiteboard into the clinic in less than three years, having recently won approval in the

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from R&D

More from Pink Sheet

Recent and Upcoming FDA Advisory Committee Meetings

 
• By Sue Sutter

Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered.

UK Health Data Research Service Looks ‘Encouraging’ For Industry, But Implementation Details Will Be Key

 
• By Anabel Costa-Ferreira

Marcus Vass and Vladimir Murovec of international law firm Osborne Clarke tell the Pink Sheet what the government's planned HDRS might mean for industry, and how it compares with the European Health Data Space.

EU Health Data Space May Speed Up R&D Through Access To Multi-Omics & Clinical Record Data

 
• By Eliza Slawther

The European Health Data Space framework will allow companies to accelerate R&D processes and identify new molecular targets faster by facilitating centralized access to certain types of high-quality data, Finland’s Orion Pharma says.